| Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma CE Wu, A Esfandiari, YH Ho, N Wang, AK Mahdi, E Aptullahoglu, P Lovat, ... British journal of cancer 118 (4), 495-508, 2018 | 55 | 2018 |
| Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells C Ciardullo, E Aptullahoglu, L Woodhouse, WY Lin, JP Wallis, H Marr, ... Haematologica 104 (12), 2429, 2019 | 25 | 2019 |
| Splicing modulation results in aberrant isoforms and protein products of p53 pathway genes and the sensitization of B cells to non-genotoxic MDM2 inhibition E Aptullahoglu, C Ciardullo, JP Wallis, H Marr, S Marshall, N Bown, ... International Journal of Molecular Sciences 24 (3), 2410, 2023 | 6 | 2023 |
| SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia E Aptullahoglu, JP Wallis, H Marr, S Marshall, N Bown, E Willmore, ... International Journal of Molecular Sciences 24 (14), 11335, 2023 | 3 | 2023 |
| In situ detection of JAK2V617F within viable hematopoietic cells using gold nanoparticle technology S Sozer, E Aptullahoglu, V Shivarov, AS Yavuz International Journal of Laboratory Hematology 41 (4), e95-e98, 2019 | 3 | 2019 |
| p53 as a biomarker and potential target in gastrointestinal stromal tumors CE Wu, CP Chen, WK Huang, YR Pan, E Aptullahoglu, CN Yeh, J Lunec Frontiers in Oncology 12, 872202, 2022 | 2 | 2022 |
| Inhibition of WIP1/PPM1D phosphatase by GSK2830371 potentiates the growth inhibitory and cytotoxic activity of MDM2 antagonists (nutlin-3, RG7388 and HDM201) in cutaneous … CE Wu, A Esfandiari, YH Ho, C Shepherd, AK Mahdi, E Aptullahoglu, ... Cancer Research 77 (13_Supplement), 2151-2151, 2017 | 1 | 2017 |
| The p53-MDM2 antagonist RG7388 activates p53 and induces a predominantly pro-apoptotic gene expression signature in chronic lymphocytic leukemia C Ciardullo, L Woodhouse, E Aptullahoglu, JP Wallis, HJ Marr, ... Blood 128 (22), 893, 2016 | 1 | 2016 |
| RNA-Sequencing Reveals Candidate Genes/Pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in TP53 Wild-Type Chronic Lymphocytic Leukemia J Lunec, E Aptullahoglu, S Nakjang, J Wallis, H Marr, S Marshall, ... | | 2024 |
| Targeting the MDM2-p53 interaction: evaluation of a novel, potent MDM2-p53 antagonist in patient-derived CLL cells E Willmore, E Aptullahoglu, Y Zhao, S Kyle, H Thomas, M Ahn, L Fazal, ... LEUKEMIA & LYMPHOMA 61, 81-81, 2020 | | 2020 |
| The spliceosome inhibitor E7107 induces a dose-dependent cytotoxicity in CLL cells and produces aberrantly spliced transcripts and protein products of p53 pathway genes E Aptullahoglu, J Wallis, H Marr, S Marshall, E Willmore, J Lunec LEUKEMIA & LYMPHOMA 61, 266-267, 2020 | | 2020 |
| PO-445 E7107 treatment results in aberrantly spliced transcripts and protein products of P53 pathway genes E Aptullahoglu, JP Wallis, H Marr, S Marshall, E Willmore, J Lunec ESMO Open 3, A197, 2018 | | 2018 |
| In-Cell Detection By Flow Cytometry of JAK2 V617F Mutation Using Gold Nanoflares E Aptullahoglu, I Uslu, AS Yavuz, V Shivarov, S Sozer Blood 124 (21), 4586, 2014 | | 2014 |
| JAK2V617F mutasyonunun altın nanoflares kullanılarak tespiti E Aptullahoğlu Sağlık Bilimleri Enstitüsü, 0 | | |
